Key Details
Price
$16.51PE Ratio
48.56Annual ROE
-4.89%Beta
0.75Events Calendar
Next earnings date:
Feb 20, 2025Recent quarterly earnings:
Oct 30, 2024Recent annual earnings:
Feb 20, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
Avanos Medical (AVNS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
AVNS' strong product line and focus on R&D raise optimism about the stock.
AVNS, BATRK and ELV have been added to the Zacks Rank #5 (Strong Sell) List on December 11, 2024.
ALPHARETTA, Ga. , Nov. 12, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced that Michael Greiner, interim chief executive officer, will participate in an analyst-led fireside chat at the Stifel 2024 Healthcare Conference at the Lotte New York Palace in New York on Tuesday, Nov. 19 at approximately 3:35 p.m.
ALPHARETTA, Ga. , Nov. 11, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) announced today that the Centers for Medicare and Medicaid Services (CMS) has issued its final Medicare Hospital Outpatient Prospective Payment System (OPPS) and Medicare Ambulatory Surgical Center (ASC) Payment System rule for 2025.
Advancement to reduce dislodgement in feeding tube retention systems ALPHARETTA, Ga. , Nov. 5, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today announced the launch of its newly designed CORGRIP SR Nasogastric/Nasointestinal Tube Retention System, further expanding its comprehensive Enteral Feeding portfolio.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Avanos Medical, Inc. AVNS reported third-quarter 2024 adjusted earnings per share (EPS) from continuing operations of 36 cents, up 20% year over year. The bottom line met the Zacks Consensus Estimate.
Avanos Medical Inc. (NYSE:AVNS ) Q3 2024 Results Conference Call October 30, 2024 9:00 AM ET Company Participants Scott Galovan - Vice President of Strategy & Corporate Development Gary Blackford - Chairman Michael Greiner - Senior VP, CFO & Chief Transformation Officer Conference Call Participants Kristen Stewart - CL King Danny Stauder - Citizens JMP Operator Good morning, ladies and gentlemen, and welcome to the Avanos Medical, Avanos Third Quarter 2024 Earnings Call. [Operator Instructions] This call is being recorded on Wednesday, October 30, 2024.
Avanos Medical (AVNS) came out with quarterly earnings of $0.36 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.30 per share a year ago.
FAQ
- What is the ticker symbol for Avanos Medical?
- Does Avanos Medical pay dividends?
- What sector is Avanos Medical in?
- What industry is Avanos Medical in?
- What country is Avanos Medical based in?
- When did Avanos Medical go public?
- Is Avanos Medical in the S&P 500?
- Is Avanos Medical in the NASDAQ 100?
- Is Avanos Medical in the Dow Jones?
- When was Avanos Medical's last earnings report?
- When does Avanos Medical report earnings?
- Should I buy Avanos Medical stock now?